LLY · News · 20260825N

Product / Drug Pipeline Progress - retatrutide

ELI LILLY & Co · 2026-08-25 · Importance 26 · Surprise 24

Retatrutide was identified as a promising Lilly pipeline candidate in the expanding obesity market. The product is positioned alongside Mounjaro and Zepbound as a potential future contributor to Lilly’s weight-loss portfolio. Its development could reinforce Lilly’s competitive position against Novo Nordisk as oral and injectable obesity treatments expand. The digest does not provide clinical-stage, efficacy, or launch-timing details.

Key facts